Showing 3151-3160 of 3223 results for "".
- Thomas Burns, CEO of Glaukos, Joins Avedro’s Board of Directorshttps://modernod.com/news/thomas-burns-ceo-of-glaukos-joins-avedros-board-of-directors/2479974/Avedro announced that Thomas W. Burns has been elected to its board of directors. Mr. Burns has a proven track record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns is President, Chief Executive Officer and a mem
- Heidelberg Engineering Announces Leadership Changeshttps://modernod.com/news/heidelberg-engineering-announces-leadership-changes/2480004/Heidelberg Engineering announced changes to the leadership team. Ali Tafreshi who has served in sales, marketing and research capacities in both the United States and German organizations
- US to Develop Drug Import Policy Aimed at Countering Price Hikeshttps://modernod.com/news/us-to-develop-drug-import-policy-aimed-at-countering-price-hikes/2480005/US Health and Human Services Secretary Alex Azar on Thursday directed the FDA to explore how to safely import prescription drug products from other countries “in the event of a dramatic price increase for a drug produced by one manufacturer and not protected by patents or exclusivities.R
- Sheraz Daya, MD, Introduces the Daya ICL Forcepshttps://modernod.com/news/sheraz-daya-md-introduces-the-daya-icl-forceps/2480015/In partnership with MST, Sheraz Daya, MD, has co-created an ICL loading system that ensures true confidence in loading and positioning. The design of the forceps allow the user to pull the ICL into the injection cartr
- Some AMD Patients May Not Respond to Intravitreal Aflibercepthttps://modernod.com/news/some-amd-patients-may-not-respond-to-intravitreal-aflibercept/2480030/Although intravitreal aflibercept is effective in the great majority of treatment-naive cases of neovascular age-related macular degeneration (AMD), the drug may not work for a small subgroup of patients with choroidal vascular hyperpermeability, Japanese researchers say, according to a
- Study: Combined Cataract Surgery Ups Postop Endophthalmitis Riskhttps://modernod.com/news/study-combined-cataract-surgery-ups-postop-endophthalmitis-risk/2480042/Patients who undergo combined cataract surgery, or removal of cataracts combined with treatment of other eye disorders during the same procedure, have higher incidence of acute postoperative endophthalmitis (acute POE) compared with those who have cataract surgery alone, results of a French natio
- Novaliq’s NovaTears Treatment for Evaporative Dry Eye Disease is Now Available across Australia and New Zealandhttps://modernod.com/news/novaliqs-novatears-treatment-for-evaporative-dry-eye-disease-is-now-available-across-australia-and-new-zealand/2480059/Novaliq announced that NovaTears, a novel topical treatment of dry eye disease and meibomian gland dysfunction (MGD), is now also available in Australia. Just 8 months after launching in New Zealand, AFT Pharmaceuticals Ltd (AFT) has achieved registration of NovaTears in Australia. AFT, a
- Bausch + Lomb Announces Licensing Agreement With Tangible Science for Use of Hydra-Peg Custom Contact Lens Coatinghttps://modernod.com/news/bausch-lomb-announces-licensing-agreement-with-tangible-science-for-use-of-hydra-peg-custom-contact-lens-coating/2480063/Bausch + Lomb announced that it has entered into a worldwide licensing agreement with Tangible Science, allowing Bausch + Lomb to offer the Tangible Hydra-PEG advanced contact lens coating technology for use with several of its Boston gas permeable (GP) materials and scleral lenses. Terms
- EyeQue Raises $11.2 Million in Series B to Bring At-Home Vision Testing to the Masseshttps://modernod.com/news/eyeque-raises-11-2-million-in-series-b-to-bring-at-home-vision-testing-to-the-masses/2480065/EyeQue announced it has raised $11.2 million in a Series B round from existing investors. The funds will be used to help the company on its mission to eliminate extraneous trips to the optometrist and make at-home vision testing a reality for people across the globe. EyeQue’s patented technology
- Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45 Million Public Offering of Common Stockhttps://modernod.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/Aerpio Pharmaceuticals announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announce